Elekta gets Gamma Knife orders worth $41 million:
This article was originally published in Clinica
Executive Summary
Stockholm, Sweden firm Elekta continues to roll out its Leksell Gamma Knife radiosurgery equipment for treating brain cancer and functional disorders. The company has recently signed agreements for delivery of Leksell equipment in the US, Japan, China, Taiwan and France, for a total of SKr315m ($41m). The orders will be delivered during the next two fiscal years, ending April 2005. They include 11 new units and several upgrades and reloads.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.